ESTRO-EPTN publishes guidance on independent dose calculation and log-based QA in particle therapy

New ESTRO-EPTN recommendations define validated, risk-based pathways for introducing independent dose calculation and machine log-file QA in scanned particle therapy.

KEY POINTS

  • The ESTRO-European Particle Therapy Network (ESTRO-EPTN) developed consensus-based recommendations for patient-specific quality assurance in scanned proton and other light-ion therapies. The guidance focuses on independent dose calculation (IDC) and machine log-file-based QA, covering clinical commissioning, acceptance thresholds, risk assessment, machine QA integration, traceability, and progressive implementation.
  • The guidelines distinguish between two complementary verification functions: plan-based IDC independently recalculates the intended three-dimensional dose, while log-file analysis evaluates recorded treatment delivery parameters such as spot positions and monitor units. Combining both methods can address calculation, transfer, and delivery-related failure modes that may not be adequately identified through conventional phantom measurements alone.
  • For IDC, the working group recommends Monte Carlo-based dose calculation in patient CT geometry rather than relying exclusively on analytical algorithms or homogeneous phantom recalculation. The IDC should operate independently of the treatment planning system, preferably using alternative algorithms and physics models, while dose-to-medium versus dose-to-water conventions and RBE models must be harmonized appropriately for meaningful comparison.
  • For dose comparison, global 3%/3 mm gamma analysis with a 10% low-dose threshold remains an initial reference, with more stringent or site-specific criteria such as 3%/2 mm, 2%/3 mm, or 2%/2 mm considered when justified. The authors recommend three-dimensional gamma assessment and emphasize that gamma passing rate alone is insufficient: DVHs, target and OAR clinical goals, spatial dose differences, and the distribution of gamma failures must also be evaluated.
  • The guidelines recommend introducing phantom-less QA through a documented, prospective multidisciplinary risk assessment, with representative commissioning cases and intentional error scenarios. Before substantially replacing patient-specific phantom measurements, a pragmatic minimum of six months and 100 patients of phantom-based QA experience is proposed, accompanied by demonstrated beam-delivery stability and additional machine QA.
  • Replacement of phantom measurements should be progressive and restricted to locally validated indications, rather than applied universally. The recommended framework retains monthly PSQA-like beam consistency tests and representative random or triggered measurements, while parallel IDC implementation allows departments to characterize method limitations and train staff before modifying routine workflows.
  • Log-file-based QA requires particular caution because file completeness, parameter accuracy, and access vary substantially between vendors and delivery systems. Some exported treatment records contain planned rather than independently measured parameters, while energy, gantry angle, snout position, or other critical variables may be missing; consequently, the group does not recommend universal replacement of measurements using log files and establishes minimum vendor requirements for trustworthy implementation.

CLINICAL TAKEAWAY

The ESTRO-EPTN recommendations provide a structured pathway for moving from measurement-dominated patient-specific QA toward independent Monte Carlo verification and fraction-resolved log-file analysis in scanned particle therapy. Phantom-less workflows may improve efficiency and support adaptive treatment, but they require locally validated independence, risk assessment, rigorous machine QA, and selective retention of physical measurements rather than indiscriminate replacement.

SOURCE

Physics and Imaging in Radiation Oncology

Browse more research Suggest a correction